{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:31:49Z","timestamp":1788928309850,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018429","name":"IEO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105394","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:08:25Z","timestamp":1779808105000},"page":"105394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Title: Role of O6-methylguanine DNA methyltransferase status as predictive factor for alkylatin-based chemotherapy in advanced neuroendocrine tumors: State of the art"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-6629","authenticated-orcid":false,"given":"Maria Grazia","family":"Maratta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2026.105394_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jnci\/85.3.200","article-title":"Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer","volume":"85","author":"Allred","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105394_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102899","article-title":"The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms - a systematic review","volume":"134","author":"Arrivi","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105394_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115726","article-title":"Modulating MGMT expression through interfering with cell signaling pathways","volume":"215","author":"Bai","year":"2023","journal-title":"Biochem Pharm."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105394_bib4","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/annonc\/mdv272","article-title":"Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer","volume":"26","author":"Barault","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105394_bib5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/curroncol30020106","article-title":"Prospective evaluation of MGMT-promoter methylation status and correlations with outcomes to temozolomide-based chemotherapy in well-differentiated neuroendocrine tumors","volume":"30","author":"Brighi","year":"2023","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105394_bib6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12020-017-1474-3","article-title":"Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study","volume":"60","author":"Campana","year":"2018","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105394_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1530\/ERC-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"23","author":"Cives","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105394_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000439086","article-title":"Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity","volume":"103","author":"Clewemar Antonodimitrakis","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105394_bib9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105394_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000498887","article-title":"Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses","volume":"108","author":"De Mestier","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.critrevonc.2026.105394_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000500862","article-title":"Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor","volume":"110","author":"De Mestier","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105394_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1530\/ERC-21-0034","article-title":"Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors","volume":"28","author":"De Rycke","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105394_bib13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3727\/096504021X16214197880808","article-title":"Evaluation of MGMT gene methylation in neuroendocrine neoplasms","volume":"28","author":"Della Monica","year":"2022","journal-title":"Oncol. Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105394_bib14","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1002\/cncr.29517","article-title":"Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: comparison of efficacy and search for predictive factors guiding treatment choice","volume":"121","author":"Dussol","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105394_bib15","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47642-2","article-title":"Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients","volume":"9","author":"Estival","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105394_bib17","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/wjs.12471","article-title":"Loss of O6-methylguanine-dna methyltransferase protein expression by immunohistochemistry is associated with response to capecitabine and temozolomide in neuroendocrine neoplasms","volume":"49","author":"Evans","year":"2025","journal-title":"World J. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105394_bib18","first-page":"259","article-title":"Yu X. O-6-Methylguanine-DNA methyltransferase and response to alkylation agents in neuroendocrine Tumor: a meta-analysis. JOP","volume":"18","author":"Gao","year":"2017","journal-title":"J. Pancreas"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105394_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MEG.0000000000000874","article-title":"Short article: evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors","volume":"29","author":"Girot","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00280-018-3700-y","article-title":"Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET","volume":"83","author":"Hijioka","year":"2019","journal-title":"Cancer Chemother. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105394_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100119","article-title":"Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study","volume":"6","author":"Jeong","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105394_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.dnarep.2007.03.008","article-title":"MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents","volume":"6","author":"Kaina","year":"2007","journal-title":"DNA Repair"},{"key":"10.1016\/j.critrevonc.2026.105394_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000430816","article-title":"Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects","volume":"101","author":"Koumarianou","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105394_bib24","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.21873\/anticanres.11590","article-title":"Impact of therapy sequence with alkylating agents and MGMT status in patients with advanced neuroendocrine tumors","volume":"37","author":"Krug","year":"2017","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105394_bib26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105394_bib27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105394_bib28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"61","key":"10.1016\/j.critrevonc.2026.105394_bib29","doi-asserted-by":"crossref","first-page":"104046","DOI":"10.18632\/oncotarget.22001","article-title":"Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response","volume":"8","author":"Owen","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105394_bib30","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1093\/oncolo\/oyad325","article-title":"Combined lanreotide autogel and temozolomide treatment of progressive pancreatic and intestinal neuroendocrine tumors: the phase II SONNET Study","volume":"29","author":"Pavel","year":"2024","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105394_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105394_bib32","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20194127","article-title":"Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis","volume":"40","author":"Qi","year":"2020","journal-title":"Biosci. Rep."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105394_bib33","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1002\/cncr.27392","volume":"118","author":"Quillien","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105394_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/MPA.0000000000000842","article-title":"O6-Methylguanine DNA methyltransferase status does not predict response or resistance to alkylating agents in well-differentiated pancreatic neuroendocrine tumors","volume":"46","author":"Raj","year":"2017","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PAI.0b013e31802fac2f","article-title":"MGMT immunohistochemical expression and promoter methylation in human glioblastoma","volume":"16","author":"Rodriguez","year":"2008","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62061-8","article-title":"Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management","volume":"14","author":"Rosas-Alonso","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000365514","article-title":"Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms","volume":"100","author":"Schmitt","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105394_bib39","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/carcin\/21.10.1879","article-title":"Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase","volume":"21","author":"Shiraishi","year":"2000","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12020-020-02421-2","article-title":"Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis","volume":"72","author":"Spada","year":"2021","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105394_bib41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/jcm8081224","article-title":"Safety and activity of metronomic temozolomide in second-line treatment of advanced neuroendocrine neoplasms","volume":"8","author":"Tafuto","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2026.105394_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102261","article-title":"Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis","volume":"99","author":"Trillo Aliaga","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105394_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pan.2020.12.009","article-title":"Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus","volume":"21","author":"Vi\u00fadez","year":"2021","journal-title":"Pancreatology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105394_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.2014.660","article-title":"O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents","volume":"112","author":"Walter","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105394_bib45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1200\/JCO.23.02724","article-title":"\u201cGroupe d\u2019\u00e9tude des tumeurs endocrines (GTE)\u201d and the French ENDOCAN-RENATEN network. Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)","volume":"43","author":"Walter","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105394_bib46","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1159\/000510159","article-title":"A Ki-67 index to predict treatment response to the capecitabine\/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study","volume":"111","author":"Wang","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105394_bib47","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1002\/cncr.26124","article-title":"Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy","volume":"117","author":"Welin","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105394_bib48","first-page":"4204","article-title":"Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm","volume":"7","author":"Yang","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105394_bib49","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy","volume":"9","author":"Yu","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105394_fur1","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:42:35Z","timestamp":1787107355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S1040842826002817"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105394","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Title: Role of O6-methylguanine DNA methyltransferase status as predictive factor for alkylatin-based chemotherapy in advanced neuroendocrine tumors: State of the art","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105394"}}